Background-Fetal hemoglobin (HbF) is the major modifier of the clinical course of sickle cell anemia. Its levels are highly heritable, and its interpersonal variability is modulated in part by 3 quantitative trait loci that affect HbF gene expression. Genome-wide association studies have identified single-nucleotide polymorphisms (SNPs) in these quantitative trait loci that are highly associated with HbF but explain only 10% to 12% of the variance of HbF. Combining SNPs into a genetic risk score can help to explain a larger amount of the variability of HbF level, but the challenge of this approach is to select the optimal number of SNPs to be included in the genetic risk score. Methods and Results-We developed a collection of 14 models with genetic risk score composed of different numbers of SNPs and used the ensemble of these models to predict HbF in patients with sickle cell anemia. The models were trained in 841 patients with sickle cell anemia and were tested in 3 independent cohorts. The ensemble of 14 models explained 23.4% of the variability in HbF in the discovery cohort, whereas the correlation between predicted and observed HbF in the 3 independent cohorts ranged between 0.28 and 0.44. The models included SNPs in BCL11A, the HBS1L-MYB intergenic region, and the site of the HBB gene cluster, quantitative trait loci previously associated with HbF. Conclusions-An ensemble of 14 genetic risk models can predict HbF levels with accuracy between 0.28 and 0.44, and the approach may also prove useful in other applications. (Circ Cardiovasc Genet. 2014;7:110-115.)
F etal hemoglobin (HbF) is the major modifier of the clinical features of sickle cell anemia (homozygosity for HBB glu6val) and β-thalassemia. HbF inhibits sickle hemoglobin (HbS) polymerization and compensates for the deficit of normal HbA in β-thalassemia. 1 If it were possible to know at birth the HbF level likely to be present after stabilization of this measurement at ≈5 years of age, 2 a better patient-specific prognosis might be given and HbF-inducing treatments better tailored to the individual. The γ-globin chain of HbF is encoded by the linked HBG1 and HBG2 genes. The levels of HbF in adults are highly heritable, and the production of HbF is genetically regulated by several quantitative trait loci that modulate HBG1 and HBG2 expression. [3] [4] [5] [6] Genome-wide association studies (GWAS) in sickle cell anemia have identified single-nucleotide polymorphisms (SNPs) in BCL11A, the HBS1L-MYB intergenic region, and elements linked to the HBB gene cluster that jointly explain 10% to 12% of the variability of HbF. 2, 7 However, it is possible that SNPs that are significantly associated with HbF levels but do not reach genome-wide significance may explain additional variability and be used to predict HbF levels. This is in part due to the difference in the goals of the analysis of GWAS and phenotype prediction; to increase the amount of variability explained in a phenotype, one may need to use SNPs that fall below the genome-wide significance threshold. 8 One approach to genetic risk prediction uses a summary of risk alleles in the form of a genetic risk score (GRS) as a covariate of the model. [9] [10] [11] [12] A GRS can summarize a large amount of genetic information into a single covariate, but the challenge is to identify the optimal number of SNPs to be included in the score. To overcome this challenge, we present a novel method of creating an ensemble of models with the GRS composed of a different number of SNPs to produce more robust predictions. This method extends the approach introduced in Sebastiani et al 13 for building genetic risk prediction models from casecontrol studies to predict quantitative traits. We show that an ensemble of 14 models with GRS comprising 1 to 14 SNPs that were trained in a set of 841 patients with sickle cell anemia from the Cooperative Study of Sickle Cell Disease (CSSCD) can predict HbF in 3 different cohorts of blacks with sickle cell anemia, with correlation between observed and predicted values in the range of 0.28 and 0.44.
Methods

Participants
HbF levels were measured in 841 black subjects from the CSSCD (NCT00005277) homozygous for the HbS gene or with HbS-β 0 -thalassemia. 14 The validation cohorts included 181 patients from the Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy (Walk-PHaSST) study (NCT00492531), 77 patients from a study of pulmonary hypertension in children with sickle cell disease (PUSH; NCT00495638), and 127 patients with sickle cell anemia from the Comprehensive Sickle Cell Centers Collaborative Data (C-Data) project. Subjects for all cohorts were selected based on the following criteria: >5 years of age for HbF measurement, no hydroxyurea use, and no recent transfusion. In addition, patients in the validation cohorts had hemoglobin phenotypes similar to those of the discovery set. The demographics of these studies have been described. [14] [15] [16] Some characteristics of patients with sickle cell anemia are described in Table 1 . All studies were approved by the institutional review board of each participating institution.
HbF Values
HbF was measured by alkali denaturation in the CSSCD or by high-pressure liquid chromatography. Within the range of observed HbF, both alkali denaturation and high-pressure liquid chromatography gave similar results. For CSSCD subjects, longitudinal HbF values were gathered from phases 1 through 3 of the study; only steady-state values were used (ie, measurements not taken during an acute event) and summarized by the median of longitudinal values. 2 Because HbF is known to decrease in the early years of life, we only used HbF measurements at ≥5 years of age. The cubic root transformation of HbF was used in all statistical analyses to remove asymmetry.
Genotyping
DNA from CSSCD, PUSH, Comprehensive Sickle Cell Centers
Collaborative Data (C-Data), and Walk-PHaSST samples that formed the discovery and replication cohorts was genotyped at Boston University using Illumina Human610-Quad SNP arrays with ≈600 000 SNPs. Samples were processed according to the manufacturer's protocol, and BeadStudio Software was used to make genotype calls using the Illumina predefined clusters. Samples with <95% call rate were removed, and SNPs with call rate <97.5% were reclustered. After reclustering, SNPs with call rates >97.5%, cluster separation score >0.25, excess heterozygosity between −0.10 and 0.10, and minor allele frequency >5% were retained in the analysis. We used the genome-wide identity by descent analysis in PLINK to discover unknown relatedness. 17 Pairs with identity by descent measurements >0.2 were deemed to be related, and related subjects within individual or different studies were removed. We also removed samples with inconsistent sex findings defined by heterozygosity of the X chromosome and sex recorded in the database.
Statistical Analysis
Genotype data from CSSCD were used as the training data set to develop different GRS. Initially, the association of each SNP was tested using a linear regression model adjusted for sex using the additive coding in PLINK, 17 and P values for each association were computed. No significant associations were found between HbF and the first 10 principal components computed using EIGENSOFT. 18 Lack of inflation of the associations was confirmed by the genomic inflation factor 1.003. 18 SNPs were sorted by increasing P values, starting from the most significant SNP associated with HbF (rs766432; P=2.61×10 −21 ), and the list of SNPs was pruned by removing those SNPs in high linkage disequilibrium (r 2 >0.8). If 2 SNPs were found to be in high linkage disequilibrium, the SNP with lowest P value was kept and the other SNP was removed. This process was repeated until no SNPs in high linkage disequilibrium remained, which left 500 325 SNPs. This pruned and sorted list of SNPs was used to generate a sequence of unweighted GRS for each subject in CSSCD by cumulatively adding the number of risk alleles (an allele that causes a decrease in HbF) for each SNP. The first GRS included only the most significant SNP, the second GRS was generated by adding the second SNP from the sorted list of SNPs to the first GRS, and so on, using the iterative formula:
where n is the number of SNPs, and Risk Allele i,j is the number of risk alleles carried by individual i for the jth SNP. A sequence of weighted GRS was also generated by weighting each risk allele as:
where t j is the t-statistic to test the association of jth SNP with HbF. This analysis was repeated for the first 10 000 SNPs (P<0.02185) and generated 10 000 GRS for each of the subjects in CSSCD. Each of these GRS was included as covariate in a linear regression model, and the regression coefficients of the resultant 10 000 linear regression models were estimated using least squares methods in the CSSCD data in R package. The fitted regression models were used to predict HbF using the formula:
where HbFi n , is the predicted HbF value for individual i using the nth GRS, and β β 0 1 , , , n n are the estimates of regression coefficients. Cumulative ensembles of the predictions 13, [19] [20] [21] were computed using the formula: The predictive value of genetic risk models and their ensembles was evaluated in CSSCD and in the 3 independent cohorts. The proportion of variability explained in the ensemble of GRS models in the CSSCD set was computed as the squared Pearson correlation between the predicted and observed values, whereas the predictive accuracy in independent sets was evaluated by computing the Pearson correlation between the observed and predicted values of HbF. The number of SNPs with GRS that maximized the correlation between observed and predicted values in the 3 independent cohorts was selected as the optimal number of SNPs. To evaluate the predictive value of genetic data relative to nongenetic risk factors, a nongenetic prediction model based on age, sex, and presence of α-thalassemia was estimated, and the genetic risk models were also adjusted by age, sex, and α-thalassemia. The accuracy of these additional models was assessed by the correlation between predicted and observed HbF values. Table 1 shows the patient characteristics of the 4 studies. The percentages of men and HbF concentration were approximately the same across Walk-PHaSST, C-Data, and CSSCD cohorts. The average age varied across the 4 cohorts; the CSSCD studied both children and adults; C-Data and PUSH were skewed toward pediatric patients, whereas the Walk-PHaSST cohort consisted mainly of adults. Patients in PUSH were younger and had significantly higher HbF levels (P=0.0016).
Results
The Figure An ensemble of the first 14 GRS models had the highest average correlation among all 3 data sets and explained 23.4% of the variability in HbF in the CSSCD cohort. The correlation between observed and predicted HbF using the ensemble of 14 GRS models was 0.44, 0.28, and 0.39 in the PUSH, Walk-PHaSST, and C-Data cohorts, respectively. Of these 14 SNPs, 5 were located in BCL11A; other SNPs were located in the olfactory receptor region on chromosome 11p15 and the site of the HBB gene cluster, and in the HBS1L-MYB interval on chromosome 6q, and were found previously to be associated with HbF. 2, 22, 23 Table 2 shows details of these 14 SNPs.
Adding nongenetic risk factors such as age and sex to the GRS models did not increase the amount of variability explained in HbF in the Howard and Walk-PHaSST cohorts. The nongenetic prediction model, which included information on age, α-thalassemia, and sex only, explained 6.8% of the variability in HbF in the CSSCD cohort.
It is noticeable that the genetic risk models had consistently higher predictive accuracy in the PUSH cohort in comparison with the C-Data and Walk-PHaSST cohorts. The age distribution of the CSSCD and PUSH cohorts was skewed toward children and young adolescents, whereas the age distribution of the Walk-PHaSST cohort was skewed toward adult patients ( Figure II in the Data Supplement). The exact age of patients was not available for the C-Data cohort.
Discussion
In blacks with sickle cell anemia, the HbF level does not stabilize until 5 years of age. 2 The early prediction of stable adult HbF levels might help foresee some complications of sickle cell anemia and aid in its clinical management by guiding the decision of how vigorously to pursue HbF induction therapies. Our goal was to identify methods that could combine SNPs to provide a better prediction of HbF levels compared with single SNP analysis. We developed an ensemble of GRS that predicted HbF in 3 independent cohorts. In an ensemble of GRS models, as few as 14 SNPs explained a larger fraction of the variability in HbF and better predicted HbF levels when compared with single SNP analysis or a single GRS model. Although the ensemble of GRS explains 23.4% of the variability in HbF in CSSCD cohort, it does not explain the totality of the variability in HbF that is due to heritability, estimated to be between 60% and 90%. 5, 24 This missing heritability could be due to gene-gene interactions, epigenetic factors, or multiple rare variants with small effects that GWAS are poorly designed to detect. 25 Our GRS included SNPs with a minor allele frequency >5%; however, because sickle cell anemia is a rare disease, it is possible that some major genetic modifiers are rare variants with a lower allele frequency. Nextgeneration sequencing might discover rare alleles that could be incorporated into a GRS to increase prediction accuracy. Increasing the number of genetic variants in the GRS may increase the total explained variability of HbF 26 ; however, this could lead to overfitting, and as one continues to add more genetic variants to the GRS, the prediction accuracy in independent cohorts will decrease (see the Figure) . The prediction accuracy of our weighted GRS model was similar to that of our unweighted GRS model. We hypothesize that this is due to the fact that weighted GRS models perform better when there is a difference in genetic effects; however, Table 2 shows that regression coefficients and standard errors from the GWAS of our top SNPs are all similar.
An interesting result of our analysis is the systematically higher correlation between predicted and observed HbF values in the PUSH study. This result might suggest that genetic models predict more accurately in children and young adults. Blood counts decline with advancing age in sickle cell disease and could reflect decades of bone marrow damage due to sickle vasoocclusion with relative bone marrow failure. [27] [28] [29] Perhaps the higher correlation between predicted and observed HbF levels in younger patients of the PUSH cohort is a result of gene×environment interaction, where the genetic elements regulating HbF production are not impeded by erythroid bone marrow injury associated with aging in older cohorts. However, the difference in prediction accuracy could also be due to unobservable patient characteristics not accounted for in the model. For example, the CSSCD was conducted before the establishment of hydroxyurea as a standard therapy for sickle cell anemia, and there may be survivor effects in more contemporary cohorts that are not accounted for in older cohorts. Testing these results in additional contemporary cohorts of sickle cell anemia will be necessary to explain the result.
The 14-SNP model included SNPs in the BCL11A region, the HBS1L-MYB intergenic region, and SNPs in the olfactory receptor gene cluster 5ʹ to the HBB gene complex. BCL11A downregulates HBG expression 30, 31 ; the HBS1L-MYB intergenic region might affect erythropoiesis and modulate BCL11A expression, whereas the olfactory receptor region might control the expression with the HBB gene-like cluster. 32 There are alternative methods of genetic prediction that we did not explore in this article, including combining SNP information into a haplotype-based analysis, 33, 34 multivariate regression models, and machine learning-type approaches such as support vector machines and cross-validation, 35, 36 principal component analysis, 37 and Bayesian networks. [38] [39] [40] [41] [42] In our analysis, we used traditional regression-based models and an ensemble of these models: we trained the models in discovery cohorts and examined the prediction results in independent cohorts to determine which model predicts most accurately. We investigated using a 10-fold cross-validation method to select the best number of SNPs in the discovery set. However, we noted in a large simulation study that using 10-fold cross-validation tends to underestimate the true number of SNPs (see the Data Supplement; Figure III in the Data Supplement) and noted that an ensemble of regression models seems to be more robust for prediction. This result is consistent with published literature. 43 Because the 3 test sets were used to determine the optimal number of SNPs, the replication of results in additional independent sets is necessary to confirm the results. However, the substantial agreement of prediction of the ensemble of 14 models in the 3 sets is reassuring that this result is robust.
The ensemble of GRS models explained 23.4% of the variability in HbF in CSSCD data, and the correlation between predicted and observed HbF values in the 3 independent sets ranged from 0.28 to 0.44. These numbers are higher than those reported in the literature when GRS has been used as a predictive tool. For example, a study of 3575 subjects from the Doetinchem Cohort Study computed a GRS to predict plasma total cholesterol levels, which are highly genetically determined with heritability estimated to be between 40% and 60%. 44, 45 Using 12 SNPs, they were able to explain 6.9% of the total variability in total cholesterol levels. 46 The participants in the Atherosclerosis Risk in Communities cohort of 10 745 individuals were used to construct a GRS of obesity to predict body mass index. 47, 48 The obesity GRS showed a correlation with body mass index of r=0.12 for the unweighted GRS model and r=0.13 for the weighted model. Our ensemble of GRS models of HbF can explain more phenotype variability and had a higher predictive accuracy in comparison with single SNP analyses.
One of the major goals of GWAS was to identify genetic variants that are associated with disease or measures of disease severity to be used in personalized medicine. Many studies have shown the importance of including genetic variants beyond those that meet the genome-wide association threshold of 5×10 −08 , but many of these SNP associations may be false-positives and lower the accuracy of a prediction model. 49, 50 Our study shows that the use of an ensemble of genetic risk models is robust to the inclusion of false-positive associations, and the approach may prove useful in other applications. 
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